Oppenheimer raised the firm’s price target on Ligand (LGND) to $275 from $250 and keeps an Outperform rating on the shares. The firm notes Ligand reported total revenue of $115.5M including $46.6M from royalties, $24.5M from Zelsuvmi’s out-licensing, and a $28.6M gain on Pelthos sale. Oppenheimer is bullish on Palvella’s two value-unlocking events over next 4 months, which should provide further comfort on Qtorin’s commercial opportunity. The firm sees Qtorin as a key driver of future royalties.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LGND:
- Pelthos Therapeutics acquires Xepi Cream from Biofrontera, Ferrer
- Ligand Pharmaceuticals Reports Strong Q3 Results and Raises Guidance
- Ligand price target raised to $231 from $206 at H.C. Wainwright
- Ligand reports Q3 adjusted EPS $3.09, consensus $1.89
- Ligand raises FY25 adjusted EPS view $7.40-$7.65 from $6.70-$7.00